MSM (methylsulfonylmethane)

MSM is an organosulfur compound — a DMSO metabolite — sold on the idea that it supplies sulfur for connective tissue and, better supported, that it blunts NF-κB-driven inflammatory signalling. The mechanistic case rests almost entirely on cell and animal work; there is no direct evidence that oral MSM changes human cartilage biology. What it has is a short stack of small, consistent trials.

The three trials

Kim 2006 (n=50, 6 g/day, 12 weeks): WOMAC pain fell 14.6 points on MSM versus 7.2 on placebo (p=0.041), with improved physical function. Stiffness and the aggregate symptom score did not separate — and the placebo group achieved half the MSM improvement.

Debbi 2011 (n=50, 3.375 g/day, 12 weeks): significant but small gains in WOMAC physical function and total score, while pain and stiffness did not separate from placebo. Most of the gap is the placebo arm getting worse rather than MSM getting better, and allocation ran on odd and even enrolment numbers rather than a concealed list. The authors explicitly questioned whether their own effect size was clinically meaningful — a candor worth rewarding with the caution it asks for.

Usha 2004 (n=118, 12 weeks): MSM 1.5 g/day reduced pain and swelling versus placebo, and MSM plus glucosamine outperformed either alone (pain index falling from 1.7 to 0.36 versus roughly 0.9–1.0 on monotherapy). One Indian centre, a nonstandard pain index, and about 25% dropout — and the additive combination finding has never been replicated.

Where MSM comes from

This section exists because the site's structure invites a wrong inference. Every other supplement here is paired with a whole-food route to the same building blocks — that is what the Foods section is for. MSM is the one where no such route exists, and nothing said so.

MSM is not a connective-tissue compound. Its biosynthesis is marine: algae and phytoplankton make dimethylsulfoniopropionate, which becomes dimethyl sulfide, which oxidises in the atmosphere to DMSO and then to dimethyl sulfone. The canonical survey of where it turns up in food is titled for its own scope — fruits, vegetables, grains, and beverages. The animal materials it has been isolated from or detected in are cows' milk, dried cows' blood and beef adrenal tissue, and later red deer tail-gland secretion and human saliva — none of them meat, bone, cartilage or stock.

There is no measurement of MSM in any meat, bone, cartilage, or stock. Not a low measurement — no measurement, in any indexed study. And the quantities involved make it moot: natural food concentrations run in hundredths of a part per million, against trial doses of 1.5–6 grams a day. You cannot eat your way to a studied dose of MSM from any food, which is precisely why the supplement exists.

Bone stock does carry sulfur — as methionine, cysteine, and sulfated glycosaminoglycans like chondroitin. That is almost certainly where the "bone broth is rich in MSM" claim comes from, and it is a substitution of one sulfur compound for a chemically unrelated one.

The gaps

No trial exceeds 12 weeks or ~120 participants. No imaging or structural outcomes exist anywhere in the MSM literature, and — a gap worth naming precisely for a supplement sold for joints — MSM has never been tested on a chondrocyte. Searches for in-vitro MSM cartilage-cell work return nothing; the cell literature is macrophages, osteoblasts and scaffolds.

No frankly null RCT has been published, but that is not the same as no contrary evidence. The one meta-analysis in the field, independent and from Southampton, pooled MSM with the closely related DMSO and found a non-significant 6.34 mm VAS reduction, concluding the pair are "not clinically effective" for osteoarthritis pain. It is weaker evidence than it sounds — only one of its three included trials tested MSM at all — but it belongs in the file.

Rodent work is similarly split. An independent Japanese study found MSM had no effect on cartilage formation in growing rats while reducing joint-surface degeneration in a spontaneous-osteoarthritis mouse strain, with organ atrophy at very high doses. A 2024 rat trauma model found MSM slowed radiological progression but showed no histological difference at all from control.

With an evidence base this thin, a run of small positive studies is exactly the pattern publication bias produces. A properly powered trial of several hundred patients over 6–12 months would settle it; none appears to be registered.

Dose & practical notes

Trials used 1.5–6 g/day, usually divided; the strongest single-agent result used 3 g twice daily. Where benefits appeared, they emerged by 8–12 weeks. Optimal dose is unresolved — the trialed range spans fourfold. MSM is often bundled with glucosamine in retail products; whether that adds anything rests on the single 2004 factorial trial.

Safety

This is the strongest part of the file. MSM was well tolerated at up to 6 g/day in trials, with adverse events (mild GI upset, headache) comparable to placebo, and it holds US GRAS status. No established drug interactions, though data in pregnancy and severe renal or hepatic disease are absent.

What I take from it

MSM sits in an odd spot: cheap, safe, and consistently a little better than placebo in every trial run — but every trial was small, short, and symptom-scored, and the researchers closest to the data keep flagging that "statistically significant" and "worth taking" are different claims. As a low-stakes experiment for symptoms it is reasonable; as a cartilage therapy it is simply untested, and a single properly powered trial would settle the symptom question either way.